Holen Sie sich die Stockscreener-App
59.38
0.95%
-0.375
Schlusskurs vom Vortag:
$59.76
Offen:
$60.54
24-Stunden-Volumen:
160.75K
Relative Volume:
0.22
Marktkapitalisierung:
$2.27B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-212.18M
KGV:
-9.9145
EPS:
-5.9897
Netto-Cashflow:
$-181.33M
1W Leistung:
-3.25%
1M Leistung:
+5.80%
6M Leistung:
-1.05%
1J Leistung:
+12.94%
1-Tages-Spanne:
$59.00
$62.54
1-Wochen-Bereich:
$59.00
$67.15
52-Wochen-Spanne:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Firmenname
Disc Medicine Inc
Sektor
Branche
Telefon
(617) 674-9274
Adresse
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
59.48 | 2.28B | 0 | -212.18M | -181.33M | -5.9897 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.66 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.44 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.75 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.12 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.80 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-11 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-02-27 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-01 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-17 | Eingeleitet | Raymond James | Outperform |
| 2023-04-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Eingeleitet | Stifel | Buy |
| 2023-04-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-03-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Disc Medicine Inc Aktie (IRON) Neueste Nachrichten
IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates - marketscreener.com
Disc Medicine, Inc. $IRON Stake Trimmed by Victory Capital Management Inc. - MarketBeat
Is Disc Medicine (IRON) Pricing Attractive After Recent Pullback And DCF Valuation Gap - simplywall.st
IRON Investors Lose Up to $22/Share — LEVI & KORSINSKY, LLP Investigates Disc Medicine - Morningstar
Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals - Yahoo Finance
IRON: Phase III data for bitopertin and key pipeline readouts are expected by year-end - TradingView
Disc Medicine (IRON) Is Down 8.2% After Wider 2025 Loss and ESOP Shelf FilingHas The Bull Case Changed? - simplywall.st
Disc Medicine Stock Pre-Market (+9.8%): Sector Lift on J&J Hematology Approval - Trefis
Blue Owl Capital Holdings LP Sells 20,000 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine prices upsized securities offering to raise total $250M - MSN
Disc Medicine, Inc. $IRON Shares Acquired by Vanguard Group Inc. - MarketBeat
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Insider Sell: William Savage Sells Shares of Disc Medicine Inc (IRON) - GuruFocus
William Jacob Savage Sells 7,378 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst - AOL.com
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection - AOL.com
IRON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IRON: Multiple late-stage programs advance toward pivotal data and regulatory milestones in 2024 - TradingView
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - MarketBeat
Disc Medicine, Inc. (IRON) Stock Analysis: A 50% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - FinancialContent
IRON (NASDAQ: IRON) proposed insider sales including 13,093-share 12/15/2025 sale - Stock Titan
Watertown biotech cuts 20% of staff after FDA rejects rare disease drug - The Business Journals
IRON: Wells Fargo Raises Price Target for Disc Medicine | IRON S - GuruFocus
Disc Medicine (NASDAQ:IRON) Price Target Raised to $79.00 - MarketBeat
A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings - simplywall.st
Disc Medicine Refocuses On APOLLO Trial After FDA Letter For Bitopertin - Sahm
Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf RegistrationWhat's Changed - Yahoo Finance
Disc Medicine (IRON) Announces Restructuring Following FDA Setba - GuruFocus
Disc Medicine announces workforce reduction and restructuring plan By Investing.com - Investing.com Australia
Disc Medicine announces workforce reduction and restructuring plan - Investing.com Nigeria
Insider Sell: Jean Franchi Sells Shares of Disc Medicine Inc (IR - GuruFocus
Disc Medicine (NASDAQ:IRON) CFO Sells $24,378.18 in Stock - MarketBeat
Disc Medicine Implements Restructuring Following FDA Response - TipRanks
Disc Medicine's board approves restructuring plan - marketscreener.com
Disc Medicine (IRON) CFO sells 353 shares under 10b5-1 plan - Stock Titan
Disc Medicine (IRON) trims workforce 20% after FDA letter, books $2M charge - Stock Titan
Disc Medicine (NASDAQ:IRON) Price Target Lowered to $83.00 at Truist Financial - MarketBeat
JPMorgan Chase & Co. Sells 90,737 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight - GuruFocus
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results - MarketBeat
Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Disc Medicine's 2025 Net Loss Widens - marketscreener.com
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Disc Medicine, Inc. SEC 10-K Report - TradingView
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Disc Medicine's 2025 net loss smaller than estimates - TradingView
Disc Medicine (NASDAQ: IRON) faces FDA CRL as hematology pipeline advances - Stock Titan
Disc Medicine (NASDAQ: IRON) details 2025 loss, cash runway and FDA letter - Stock Titan
Finanzdaten der Disc Medicine Inc-Aktie (IRON)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):